• 欢迎来到美国APExBIO中文站,专注小分子抑制剂、激动剂、拮抗剂及化合物库!

 


加 微 信 得 红 包
ApexBio
Search Site
相关产品
Doxorubicin
拓扑异构酶II(Topo II)抑制剂,免疫抑制抗肿瘤抗生素。

Doxorubicin

产品编号:A3966
ApexBio 的所有产品仅用作科研,我们不为任何个人用途提供产品和服务
规格 单价 库存 订购数量
10mM (in 1mL DMSO) ¥550.00 现货
10mg ¥600.00 现货
25mg ¥840.00 现货
100mg ¥1,920.00 现货

电话: 021-55669583

Email: sales@apexbio.cn

全球经销商

Sample solution is provided at 25 µL, 10mM.

引用文献

1. Zhang Y, Xia F, et al. "miR-135b-5p enhances doxorubicin-sensitivity of breast cancer cells through targeting anterior gradient 2." J Exp Clin Cancer Res. 2019 Jan 21;38(1):26. PMID:30665445
2. Goodspeed A, Jean A, et al. "A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer." Eur Urol. 2019 Feb;75(2):242-250. PMID:30414698
3. Deng Y, Li F, et al. "Triptolide sensitizes breast cancer cells to Doxorubicin through the DNA damage response inhibition." Mol Carcinog. 2018 Jun;57(6):807-814. PMID:29500880

质量控制

化学结构

Doxorubicin

相关生物数据

Doxorubicin
Cells were incubated with YSK-MEND for 24h, and then trypsinized and reseeded in 24-well plates. 24 h after reseeding, the cells were washed with PBS and incubated with DOX-containing medium for 6h. DOX-containing medium was removed, and cells were washed with PBS and recovered 18 h after fresh medium incubation. Protein concentrations determined by the CA method were regarded as a viability. Values indicate mRNA expression relative to nontreatment (NT) ± SD.

相关生物数据

CORM-3

相关生物数据

CORM-3

Doxorubicin Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Doxorubicin Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

化学性质

CAS号 23214-92-8 SDF Download SDF
别名 Adriamycin, Doxil, Adriablastin, Doxorubicinum, Myocet
化学名 (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
SMILES CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)O
分子式 C27H29NO11 分子量 543.52
溶解度 ≥27.2 mg/mL in DMSO, <2.17 mg/mL in EtOH, ≥24.8 mg/mL in H2O with ultrasonic 储存条件 Store at RT
物理性状 A solid 运输条件 试用装:蓝冰运输。
其他可选规格:常温运输或根据您的要求用蓝冰运输。
一般建议 为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。

生物活性

描述 Doxorubicin(Adriamycin)是一种抗生素,DNA拓扑异构酶II的抑制剂,DNA损伤和细胞凋亡的诱导剂。
靶点 Autophagy          
IC50            

实验操作

细胞实验 [1]:

细胞系

MDA-MB-231细胞

制备方法

可溶于DMSO。若配制更高浓度的溶液,一般步骤如下:请将试管置于37℃加热10分钟和/或将其置于超声波浴中震荡一段时间。原液于-20℃可放置数月。

反应条件

20 nM;72小时

实验结果

在MDA-MB-231细胞中,SH003 (120 μg/mL) 和Doxorubicin (20 nM) 联合使用具有协同作用。

动物实验 [2]:

动物模型

皮下注射MB231细胞的雌性无胸腺裸鼠

给药剂量

3 mg/kg/day;瘤内给药

实验结果

Doxorubicin与腺病毒MnSOD (AdMnSOD) 以及1,3-双(2-氯乙基)-1-亚硝基脲 (BCNU) 联合用药有效降低MB231肿瘤体积并延长小鼠生存期。

其它注意事项

请于室内测试所有化合物的溶解度。虽然化合物的实际溶解度可能与其理论值略有不同,但仍处于实验系统误差的允许范围内。

References:

[1]. Woo SM, Kim AJ, Choi YK, Shin YC, Cho SG, Ko SG. Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer. Phytother Res. 2016 Aug 1.

[2]. Sun W, Kalen AL, Smith BJ, Cullen JJ, Oberley LW. Enhancing the antitumor activity of adriamycin and ionizing radiation. Cancer Res. 2009 May 15;69(10):4294-300.

研究更新

4. Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol. 2013 Oct;43(10):2718-29. doi: 10.1002/eji.201242505. Epub 2013 Jul 11.
Abstract
Doxorubicin enhanced tumor infiltration by IFN-γ-secreting Tcells and decreased the content of TAMs in MMTV-neu mice.
5. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients. Gynecol Oncol. 2013 Dec;131(3):683-8. doi: 10.1016/j.ygyno.2013.09.031. Epub 2013 Oct 4.
Abstract
Although a few factors, including body composition, age, gender, changes in monocyte count and repeated dosing, have impacts on pharmacokinetic properties of PLD, clinical risk factors of ovarian cancer patients who have PPE and receive PLD are rarely identified.

产品描述

Doxorubicin(多柔比星)是从细菌培养物中分离的半合成抗癌剂[1],是一种蒽环类抗生素,被广泛用于血液癌症、实体瘤和肉瘤。

Doxorubicin插入DNA双链中,抑制DNA拓扑异构酶II的运动,停止复制过程[2]。Doxorubicin也诱导组蛋白从开放的染色质中驱逐,引起DNA损伤和表观遗传失调[3]。

Doxorubicin通过静脉给药。将近75%的doxorubicin及其代谢物与血浆蛋白结合。Doxorubicin不能穿过血脑屏障。50%的药物主要通过胆汁排泄从身体中消除,剩下的药物经过单电子还原、二电子还原和去糖苷化,其主要代谢物是一种有效的膜离子泵抑制剂,与心肌病相关[4]。

参考文献:
[1]Brayfield, A, ed.  (2013). Doxorubicin. Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 15 April 2014.
[2]Pommier Y. , et al. (2010). DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chemistry & Biology 17 (5): 421–433.
[3]Pang, B. , et al. (2013). Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nature Communications 4 (5): 1908
[4]Boucek RJ. , et al. (1987). The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. J of Biol Chem 262: 15851-15856.